公开(公告)号：US09974778B2

公开(公告)日：2018-05-22

申请号：US15316853

申请日：2015-06-10

Applicant: BRISTOL-MYERS SQUIBB COMPANY

Inventor： Pratik Devasthale ,  Fang Moore ,  James Mignone ,  Wei Wang

IPC: A61K31/4418 ,  C07D417/04 ,  C07D417/14 ,  C07D409/14 ,  C07D213/82 ,  C07D413/04 ,  A61K31/4439 ,  C07D401/04 ,  C07D213/80 ,  C07D409/04 ,  C07D401/12 ,  A61K31/444 ,  C07D401/14 ,  C07D413/12 ,  A61K45/06 ,  C07D213/74 ,  C07D405/04 ,  A61K31/4412

CPC classification number: A61K31/4418 ,  A61K31/4412 ,  A61K31/4439 ,  A61K31/444 ,  A61K45/06 ,  C07D213/74 ,  C07D213/80 ,  C07D213/82 ,  C07D401/04 ,  C07D401/12 ,  C07D401/14 ,  C07D405/04 ,  C07D409/04 ,  C07D409/14 ,  C07D413/04 ,  C07D413/12 ,  C07D417/04 ,  C07D417/14

Abstract: The present invention provides compounds of Formula (I): or a stereoisomer, a tautomer, a pharmaceutically acceptable salt, a polymorph, or a solvate thereof, wherein all of the variables are as defined herein. These compounds are monoacylglycerol acyltransferase type 2 (MGAT2) inhibitors which may be used as medicaments.

公开(公告)号：US11639353B2

公开(公告)日：2023-05-02

申请号：US17212210

申请日：2021-03-25

Applicant: BRISTOL-MYERS SQUIBB COMPANY

Inventor： Pratik Devasthale ,  Fang Moore ,  Guohua Zhao ,  Susan Nicole Pieniazek ,  Kumaravel Selvakumar ,  Suresh Dhanusu ,  Manoranjan Panda ,  Lawrence R. Marcin

IPC: C07D471/04 ,  A61K31/4375 ,  A61P1/16 ,  A61P13/12 ,  A61P11/00 ,  A61P35/00

Abstract: The present invention provides compounds of Formula (I): or stereoisomers, tautomers, or pharmaceutically acceptable salts or solvates thereof, wherein all the variables are as defined herein. These compounds are antagonists to αv-containing integrins. This invention also relates to pharmaceutical compositions comprising these compounds and methods of treating a disease, disorder, or condition associated with dysregulation of αv-containing integrins, such as pathological fibrosis, transplant rejection, cancer, osteoporosis, and inflammatory disorders, by using the compounds and pharmaceutical compositions.

公开(公告)号：US20210246136A1

公开(公告)日：2021-08-12

申请号：US17212210

申请日：2021-03-25

Applicant: BRISTOL-MYERS SQUIBB COMPANY

Inventor： Pratik Devasthale ,  Fang Moore ,  Guohua Zhao ,  Susan Nicole Pieniazek ,  Kumaravel Selvakumar ,  Suresh Dhanusu ,  Manoranjan Panda ,  Lawrence R. Marcin

IPC: C07D471/04 ,  A61P1/16 ,  A61P13/12 ,  A61P11/00 ,  A61P35/00

Abstract: The present invention provides compounds of Formula (I): or stereoisomers, tautomers, or pharmaceutically acceptable salts or solvates thereof, wherein all the variables are as defined herein. These compounds are antagonists to αv-containing integrins. This invention also relates to pharmaceutical compositions comprising these compounds and methods of treating a disease, disorder, or condition associated with dysregulation of αv-containing integrins, such as pathological fibrosis, transplant rejection, cancer, osteoporosis, and inflammatory disorders, by using the compounds and pharmaceutical compositions.

公开(公告)号：US11014922B2

公开(公告)日：2021-05-25

申请号：US16347849

申请日：2017-11-07

Applicant: BRISTOL-MYERS SQUIBB COMPANY

Inventor： Pratik Devasthale ,  Fang Moore ,  Guohua Zhao ,  Susan Nicole Pieniazek ,  Kumaravel Selvakumar ,  Suresh Dhanusu ,  Manoranjan Panda ,  Lawrence R. Marcin

IPC: C07D471/04 ,  A61K31/4375 ,  A61P1/16 ,  A61P13/12 ,  A61P11/00 ,  A61P35/00

Abstract: The present invention provides compounds of Formula (I): or stereoisomers, tautomers, or pharmaceutically acceptable salts or solvates thereof, wherein all the variables are as defined herein. These compounds are antagonists to αv-containing integrins. This invention also relates to pharmaceutical compositions comprising these compounds and methods of treating a disease, disorder, or condition associated with dysregulation of av-containing integrins, such as pathological fibrosis, transplant rejection, cancer, osteoporosis, and inflammatory disorders, by using the compounds and pharmaceutical compositions.

公开(公告)号：US20170114054A1

公开(公告)日：2017-04-27

申请号：US15316853

申请日：2015-06-10

Applicant: BRISTOL-MYERS SQUIBB COMPANY

Inventor： Pratik Devasthale ,  Fang Moore ,  James Mignone ,  Wei Wang

IPC: C07D417/14 ,  C07D213/82 ,  A61K31/4418 ,  C07D413/04 ,  A61K31/4439 ,  C07D401/04 ,  C07D417/04 ,  C07D213/80 ,  C07D409/04 ,  C07D401/12 ,  A61K31/444 ,  C07D401/14 ,  C07D413/12 ,  A61K45/06 ,  C07D213/74 ,  C07D405/04 ,  C07D409/14

CPC classification number: A61K31/4418 ,  A61K31/4412 ,  A61K31/4439 ,  A61K31/444 ,  A61K45/06 ,  C07D213/74 ,  C07D213/80 ,  C07D213/82 ,  C07D401/04 ,  C07D401/12 ,  C07D401/14 ,  C07D405/04 ,  C07D409/04 ,  C07D409/14 ,  C07D413/04 ,  C07D413/12 ,  C07D417/04 ,  C07D417/14

Abstract: The present invention provides compounds of Formula (I): or a stereoisomer, a tautomer, a pharmaceutically acceptable salt, a polymorph, or a solvate thereof, wherein all of the variables are as defined herein. These compounds are monoacylglycerol acyltransferase type 2 (MGAT2) inhibitors which may be used as medicaments.